Armata Pharmaceuticals ARMP
- Market cap
- $106M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −24.3%
Armata Pharmaceuticals' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $8M−5% | $7.9M−17% | $8M−17% | $8.5M+3% | $9.5M+19% | $8.5M+7% | $5.4M−32% | $6.4M−25% | $5.8M−39% | $6.1M−28% | $6.1M+13% | $7.6M+19% |
| SG&A | $3.6M+130% | $3.2M+76% | $3.2M+25% | $3.4M+46% | $3.2M−10% | $3.3M+5% | $3.3M+2% | $2.6M−24% | $3.1M−4% | $3.4M+3% | $3.5M+7% | $5.2M+100% |
| −$10.3M+20% | −$9.6M−7% | −$10.2M−10% | −$11.9M+24% | −$9.8M−6% | −$10.5M+10% | −$8.2M−20% | −$6.8M−43% | −$7.8M−20% | −$13.8M+31% | −$8.8M+7% | −$10.3M+51% | |
| Interest expense | $1.2M | $1.4M | $1.8M | $2.7M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$31.2M+262% | −$19.8M+92% | −$25M+73% | $9M | −$5.5M−82% | $2.6M | −$6.5M−74% | −$16.3M | −$26.7M+387% | −$124.3M | −$115.3M+1666% | $74.1M |
| −$0.86+258% | −$0.55+90% | −$0.69+73% | −$0.25+47% | −$0.15−83% | $0.04 | −$0.20−71% | −$0.45+80% | −$0.74+393% | −$3.42 | −$3.16+1480% | −$0.27−40% | |
| 36.1M+0% | 36.1M+0% | 36.1M+0% | 58.2M+3% | 36.2M+0% | 59.1M+64% | 59.5M+65% | 36.2M−38% | 36.2M+0% | 36.4M−39% | 36.5M−39% | 62M+71% |
EPS, diluted: 11 periods, Q4 FY13 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY13: share-days: the 12-month average less the 9-month, weighted by days. 11 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Armata Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ARMPArmata Pharmaceuticals | $106M | n/m | n/a | n/m | n/m | n/m | |
| KEQUKewaunee Scientific | $96.7M | 12.1× | 13.6× | 0.3× | +5% | 3.0% | |
| ICCCImmucell | $95.9M | 132× | 44.1× | 3.1× | +8% | 2.6% | |
| LFVNLifevantage | $73.5M | 14.7× | 19.4× | 0.4× | −20% | 2.8% | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| SPROSpero Therapeutics | $60.6M | 9.5× | 9.5× | 1.3× | −3% | 15.7% | |
| APTAlpha Pro Tech | $56.3M | 13.5× | 14.8× | 0.9× | +6% | 6.8% | |
| PLXProtalix BioTherapeutics | $206.3M | 11.1× | 33.6× | 2.6× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $211.5M | 11.9× | 20.2× | 0.4× | +7% | 3.7% | |
| ELMDElectromed | $223.9M | 20.4× | 29.0× | 3.0× | +15% | 15.3% | |
| UTMDUtah Medical Products | $224.6M | 21.5× | 20.9× | 6.2× | −7% | 29.0% | |
| Peer median | $140.6M | 14.1× | 19.8× | 1.8× | +6% | 11.0% |
More on Armata Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .